Review
Endocrinology & Metabolism
Johanna Melin, Maria Forslund, Simon Alesi, Terhi Piltonen, Daniela Romualdi, Poli Mara Spritzer, Chau Thien Tay, Alexia Pena, Selma Feldman Witchel, Aya Mousa, Helena Teede
Summary: This review evaluates the effectiveness of metformin and lifestyle modification compared with placebo in the management of PCOS and will inform the forthcoming, 2023 evidence-based PCOS guidelines. The results showed that metformin can reduce body mass index, insulin resistance, fasting glucose, waist-hip ratio, total cholesterol, low-density lipoprotein, and triglycerides in PCOS patients. Therefore, metformin should be considered as an efficacious adjunct to lifestyle interventions in adults with PCOS, especially for those with a higher BMI.
EUROPEAN JOURNAL OF ENDOCRINOLOGY
(2023)
Article
Endocrinology & Metabolism
Emma Oberg, Liselotte Blomberg, Torbjorn Akerstedt, Angelica Linden Hirschberg
Summary: This study compared sleep variables in women with PCOS and controls, and assessed the impact of behavioral modification intervention on sleep. The results showed that women with PCOS had shorter sleep duration and worse sleep efficiency, but their total sleep time at night was within the normal range. Behavioral modification intervention reduced daytime sleep duration and improved sleep behavior.
FRONTIERS IN ENDOCRINOLOGY
(2023)
Article
Medicine, General & Internal
Rui-Lin Ma, Yan Deng, Yan-Fang Wang, Shi-Yang Zhu, Xue-Song Ding, Ai-Jun Sun
Summary: The study demonstrated that once-weekly exenatide combined with MET was more effective than MET alone in overweight/obese women with PCOS, leading to weight reduction, improvement in BMI and waist circumference, and enhanced insulin sensitivity, with acceptable short-term side effects.
CHINESE MEDICAL JOURNAL
(2021)
Article
Nursing
Hee Kyung Choi, Seon Heui Lee, Soo Yeon Yang
Summary: This study developed an integrated mobile application for lifestyle modifications in women with PCOS, taking into consideration the systematic review and needs analysis. The application includes diet and exercise therapy, weight and menstrual period management, questionnaires and disease information, as well as personalized counseling and goal achievement motivation.
JOURNAL OF CLINICAL NURSING
(2023)
Review
Endocrinology & Metabolism
Huamin Zeng, Ying Zhang, Sikai Huang, Jinghua Wu, Wenrui Ren, Lingru Zhou, Leneng Huang, Yuyin Ye
Summary: Metformin combined with spironolactone therapy may be more effective in reducing BMI and serum androgen levels in PCOS patients. However, it does not have a significant effect on hirsutism score or gonadotropin hormone levels, and is not associated with an elevation in side-effects. When the treatment course is greater than 6 months, combination therapy can effectively reduce FBG and improve insulin resistance.
FRONTIERS IN ENDOCRINOLOGY
(2023)
Article
Obstetrics & Gynecology
Marissa Steinberg Weiss, Andrea Hsu Roe, Kelly C. Allison, William C. Dodson, Penny M. Kris-Etherton, Allen R. Kunselman, Christy M. Stetter, Nancy I. Williams, Carol L. Gnatuk, Stepanie J. Estes, David B. Sarwer, Christos Coutifaris, Richard S. Legro, Anuja Dokras
Summary: The study found a high prevalence of female sexual dysfunction among women with PCOS, but lifestyle intervention and the combined treatment of lifestyle intervention and oral contraceptive pills can improve sexual function in these patients, especially in terms of sexual desire.
FERTILITY AND STERILITY
(2021)
Article
Endocrinology & Metabolism
Qing Wen, Song Fang, Yanjing Liang, Yuting Tian, Yiding Chen, Jun Yuan, Qiu Chen
Summary: This study aimed to observe the effect of beinaglutide combined with metformin versus metformin alone on weight loss and metabolic profiles in obese patients with polycystic ovary syndrome. The results showed that the combined treatment was more effective in reducing weight, body mass index, waist circumference, and waist to height ratio compared to metformin monotherapy.
FRONTIERS IN ENDOCRINOLOGY
(2023)
Article
Endocrinology & Metabolism
Qingjie Peng, Xiaojiang Chen, Xiaoxia Liang, Jiahui Ouyang, Qiangqiang Wang, Shuai Ren, Haibo Xie, Chunhong Wang, Yaqun Sun, Xin Wu, Hetao Liu, Changchun Hei, Miao Sun, Qing Chang, Xinrui Liu, Guangyong Li, Rui He
Summary: The study investigated the effect of metformin on PCOS using a PCOS mouse model and explored the mechanism of metformin in regulating PCOS mice through the ferroptosis pathway. The results showed that metformin not only improved body weight and metabolic disorders but also improved ovarian dysfunction in PCOS mice.
FRONTIERS IN ENDOCRINOLOGY
(2023)
Article
Endocrinology & Metabolism
Izabela Chudzicka-Strugala, Anna Kubiak, Beata Banaszewska, Barbara Zwozdziak, Martyna Siakowska, Leszek Pawelczyk, Antoni J. Duleba
Summary: The study demonstrated that in women with PCOS, lifestyle modifications combined with synbiotic supplementation can significantly decrease body weight, waist circumference, hip circumference, and thigh circumference, as well as lead to a significant reduction in serum testosterone levels.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2021)
Article
Endocrinology & Metabolism
Izabela Chudzicka-Strugala, Anna Kubiak, Beata Banaszewska, Barbara Zwozdziak, Martyna Siakowska, Leszek Pawelczyk, Antoni J. Duleba
Summary: The study found that synbiotic supplementation can enhance the effects of lifestyle modifications on weight and testosterone levels in patients with PCOS, leading to significant improvements.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2021)
Article
Endocrinology & Metabolism
Jiaqi Zhang, Chuan Xing, Xiangyi Cheng, Bing He
Summary: This study compared the efficacy and safety of CANA/MET combination therapy and MET monotherapy in overweight and obese women with PCOS. The results suggest that CANA/MET combination therapy may be similar to MET monotherapy in improving menstrual frequency, weight control, hyperandrogenemia, and relieving insulin resistance.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Article
Endocrinology & Metabolism
Chuan Xing, Han Zhao, Jiaqi Zhang, Bing He
Summary: The study aimed to observe the effects of MET monotherapy and MET plus LIRA combination therapy on gonadal and metabolic profiles in overweight patients with PCOS. The results showed that both MET monotherapy and MET plus LIRA combination therapy improved glucose metabolism and relieved insulin resistance in overweight patients with PCOS. Furthermore, MET plus LIRA combination therapy was more effective in improving reproductive abnormalities and hyperandrogenemia compared to MET monotherapy.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Article
Behavioral Sciences
Sila Cetik, Aylin Acikgoz, Bulent Okan Yildiz
Summary: This study found that taste perception is reduced in PCOS patients compared to healthy women, but there is no significant difference in eating behavior. The free androgen index is associated with taste function scores, and short-term oral contraceptive use does not alter taste functions in the syndrome.
Review
Obstetrics & Gynecology
Zheng-Rong Ye, Can-Qun Yan, Nianchun Liao, Si-Hua Wen
Summary: Polycystic ovary syndrome (PCOS) is an endocrine disorder that affects women of childbearing age, causing reproductive dysfunction, hyperinsulinemia, and obesity. This meta-analysis compared the effectiveness and safety of exenatide, a glucagon-like peptide-1 receptor agonist, with metformin, an insulin sensitizer, in treating PCOS patients. The results showed that exenatide was more effective in increasing pregnancy rate, ovulation rate, decreasing body mass index, and improving insulin resistance compared to metformin. However, more high-quality studies are needed to provide stronger evidence for the use of exenatide in this patient population.
REPRODUCTIVE SCIENCES
(2023)
Article
Medicine, General & Internal
Robert Krysiak, Karolina Kowalcze, Witold Szkrobka, Boguslaw Okopien
Summary: The aim of this study was to determine if the androgen status modulates the impact of metformin on plasma prolactin levels in women. The results showed that the drug decreased total and monomeric prolactin and increased luteinizing hormone (LH) in control subjects. In women with polycystic ovary syndrome (PCOS), metformin reduced LH, LH/FSH ratio, testosterone, and free androgen index (FAI).
JOURNAL OF CLINICAL MEDICINE
(2023)